GNTA Genenta Science
- 3.190
- -0.130-3.92%
Genenta Science News
Genenta Science Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)
Buy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy Platform
Genenta Science SpA Sponsored ADR (GNTA) Gets a Buy From H.C. Wainwright
Roth MKM Assumes Genenta Science at Buy, Announces Price Target of $15
H.C. Wainwright Sticks to Its Buy Rating for Genenta Science SpA Sponsored ADR (GNTA)
Genenta Science SpA Sponsored ADR (GNTA) Gets a Buy From Maxim Group
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Arcutis Biotherapeutics (ARQT) and Genenta Science SpA Sponsored ADR (GNTA)
H.C. Wainwright Keeps Their Buy Rating on Genenta Science SpA Sponsored ADR (GNTA)
Genenta Science Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Genenta Science, Maintains $25 Price Target
Genenta Science Analyst Ratings
EF Hutton Initiates Coverage On Genenta Science With Buy Rating, Announces Price Target of $15
Maxim Group Remains a Buy on Genenta Science SpA Sponsored ADR (GNTA)
HC Wainwright Initiates Genenta Science at Buy with $25 Price Target
Genenta Science Initiated at Buy by HC Wainwright & Co.
Genenta Science Price Target Announced at $25.00/Share by HC Wainwright & Co.
Genenta Science analyst ratings
HC Wainwright & Co. Initiates Coverage On Genenta Science with Buy Rating, Announces Price Target of $25
Analysis
Price Target
No Data
